Vixiar Medical, Inc.

Vixiar Medical, Inc. develops innovative non-invasive devices for monitoring cardiopulmonary diseases, focusing on improving clinical outcomes and economic efficiency in healthcare settings. Founded in 2014, Vixiar Medical, Inc. is based in Baltimore, US, and specializes in creating devices for monitoring cardiac conditions.

The company has completed three investment deals, with its latest funding round occurring on March 20, 2019, raising USD 1. 5 mn from investors including Emerald Development Managers, MMG Ventures, Abell Foundation, and Maryland Technology Development Corporation. Kevin Thibodeau serves as the CEO of the company. Vixiar Medical specializes in the development of non-invasive devices designed for monitoring cardiopulmonary diseases, with a focus on those that impose significant clinical and economic challenges.

Their flagship product, the Vixiar Indicor™, is a hand-held device that assesses cardiac filling pressure in various healthcare settings, including homes, physician offices, nursing homes, and hospitals. This device offers a patient-friendly alternative to traditional cardiac assessment methods that are often labor-intensive, costly, or invasive, targeting healthcare professionals and facilities prioritizing efficient monitoring of heart failure patients. Vixiar’s products focus primarily on markets in North America and Europe, addressing the need for enhanced cardiopulmonary monitoring solutions. Vixiar Medical generates revenue through direct sales of the Vixiar Indicor™ to healthcare institutions and providers.

Their transaction structure includes direct-to-consumer sales and partnerships with healthcare facilities, facilitating streamlined distribution and immediate access to their monitoring solutions. Clients engage in one-time purchases of the Indicor™, aimed at enhancing patient assessment processes without the burden of recurring subscription models. Pricing strategies reflect a commitment to providing cost-effective alternatives to existing cardiac monitoring methods, ensuring accessibility for a broad client base within the healthcare sector. Vixiar Medical, Inc.

plans to utilize the recent funding of USD 1. 5 mn raised in March 2019 to support the development and launch of new products aimed at improving cardiac monitoring technology. The company is focusing on expanding its market presence in both North America and Europe, targeting specific healthcare institutions and providers for future collaborations. The funding will also facilitate enhancements to their existing products, ensuring they remain competitive in the evolving healthcare landscape.